Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
Gespeichert in:
| Veröffentlicht in: | Blood 2022-11, Vol.140 (Supplement 1), p.6760-6762 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6762 |
|---|---|
| container_issue | Supplement 1 |
| container_start_page | 6760 |
| container_title | Blood |
| container_volume | 140 |
| creator | Apperley, Jane F. Cortes, Jorge E. Jabbour, Elias Hochhaus, Andreas Hughes, Timothy Chuah, Charles de Lavallade, Hugues Deininger, Michael W. Lipton, Jeffrey H. Lomaia, Elza Maness, Lori Mauro, Michael McCloskey, James Moiraghi, Beatriz Pavlovsky, Carolina Rojas, Christine Rousselot, Philippe Sacha, Tomasz Talpaz, Moshe Turkina, Anna Sutton, Maria Undurraga Ren, Xiaowei Vorog, Alexander Rosti, Gianantonio |
| description | |
| doi_str_mv | 10.1182/blood-2022-157956 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_157956</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122045645</els_id><sourcerecordid>S0006497122045645</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1856-e6f0a63bf31e68e7eeb643293473173e8acbae1474366b0652a8cd74d4e57a9c3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhq0KpC6FB-A2F6RycGs7iZMtpzaidKWsNirLOXKcidY0iVe2t6iPwHvwSDwBT4K7KVdOM2PN_431_4S85-yC80JctoO1HRVMCMqzfJnJE7LgmSgoY4K9IgvGmKTpMuen5I333xnjaSKyBfm9tgPqw6Ac3KPf28kj2B7-_PzF2Qe4Ke-vrq5vKr76CisPtcPO6GAejzu19ebYbw5B2xE9mAm2DlUYcQo04owPagpQq2Dii4cfJuyg3Dk7GQ31TsVb_6b1Ew7WdFDh4QFHo-C8rGm5rj7OROxmcW2nCJtMC72zI4QdvnAEbPYhcrbOqOEted2rweO7l3pGvt1-3pZ3tNp8WZXXFdW8yCRF2TMlk7ZPOMoCc8RWRleWSZonPE-wULpVyNM8TaRsmcyEKnSXp12KWa6WOjkjfOZqZ7132Dd7Z0blnhrOmudYmmMszXMszRxL1HyaNRg_9mjQNV5Hd3R01qEOTWfNf9R_AXril8A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Apperley, Jane F. ; Cortes, Jorge E. ; Jabbour, Elias ; Hochhaus, Andreas ; Hughes, Timothy ; Chuah, Charles ; de Lavallade, Hugues ; Deininger, Michael W. ; Lipton, Jeffrey H. ; Lomaia, Elza ; Maness, Lori ; Mauro, Michael ; McCloskey, James ; Moiraghi, Beatriz ; Pavlovsky, Carolina ; Rojas, Christine ; Rousselot, Philippe ; Sacha, Tomasz ; Talpaz, Moshe ; Turkina, Anna ; Sutton, Maria Undurraga ; Ren, Xiaowei ; Vorog, Alexander ; Rosti, Gianantonio</creator><creatorcontrib>Apperley, Jane F. ; Cortes, Jorge E. ; Jabbour, Elias ; Hochhaus, Andreas ; Hughes, Timothy ; Chuah, Charles ; de Lavallade, Hugues ; Deininger, Michael W. ; Lipton, Jeffrey H. ; Lomaia, Elza ; Maness, Lori ; Mauro, Michael ; McCloskey, James ; Moiraghi, Beatriz ; Pavlovsky, Carolina ; Rojas, Christine ; Rousselot, Philippe ; Sacha, Tomasz ; Talpaz, Moshe ; Turkina, Anna ; Sutton, Maria Undurraga ; Ren, Xiaowei ; Vorog, Alexander ; Rosti, Gianantonio</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-157956</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.6760-6762</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1856-e6f0a63bf31e68e7eeb643293473173e8acbae1474366b0652a8cd74d4e57a9c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Apperley, Jane F.</creatorcontrib><creatorcontrib>Cortes, Jorge E.</creatorcontrib><creatorcontrib>Jabbour, Elias</creatorcontrib><creatorcontrib>Hochhaus, Andreas</creatorcontrib><creatorcontrib>Hughes, Timothy</creatorcontrib><creatorcontrib>Chuah, Charles</creatorcontrib><creatorcontrib>de Lavallade, Hugues</creatorcontrib><creatorcontrib>Deininger, Michael W.</creatorcontrib><creatorcontrib>Lipton, Jeffrey H.</creatorcontrib><creatorcontrib>Lomaia, Elza</creatorcontrib><creatorcontrib>Maness, Lori</creatorcontrib><creatorcontrib>Mauro, Michael</creatorcontrib><creatorcontrib>McCloskey, James</creatorcontrib><creatorcontrib>Moiraghi, Beatriz</creatorcontrib><creatorcontrib>Pavlovsky, Carolina</creatorcontrib><creatorcontrib>Rojas, Christine</creatorcontrib><creatorcontrib>Rousselot, Philippe</creatorcontrib><creatorcontrib>Sacha, Tomasz</creatorcontrib><creatorcontrib>Talpaz, Moshe</creatorcontrib><creatorcontrib>Turkina, Anna</creatorcontrib><creatorcontrib>Sutton, Maria Undurraga</creatorcontrib><creatorcontrib>Ren, Xiaowei</creatorcontrib><creatorcontrib>Vorog, Alexander</creatorcontrib><creatorcontrib>Rosti, Gianantonio</creatorcontrib><title>Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhq0KpC6FB-A2F6RycGs7iZMtpzaidKWsNirLOXKcidY0iVe2t6iPwHvwSDwBT4K7KVdOM2PN_431_4S85-yC80JctoO1HRVMCMqzfJnJE7LgmSgoY4K9IgvGmKTpMuen5I333xnjaSKyBfm9tgPqw6Ac3KPf28kj2B7-_PzF2Qe4Ke-vrq5vKr76CisPtcPO6GAejzu19ebYbw5B2xE9mAm2DlUYcQo04owPagpQq2Dii4cfJuyg3Dk7GQ31TsVb_6b1Ew7WdFDh4QFHo-C8rGm5rj7OROxmcW2nCJtMC72zI4QdvnAEbPYhcrbOqOEted2rweO7l3pGvt1-3pZ3tNp8WZXXFdW8yCRF2TMlk7ZPOMoCc8RWRleWSZonPE-wULpVyNM8TaRsmcyEKnSXp12KWa6WOjkjfOZqZ7132Dd7Z0blnhrOmudYmmMszXMszRxL1HyaNRg_9mjQNV5Hd3R01qEOTWfNf9R_AXril8A</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Apperley, Jane F.</creator><creator>Cortes, Jorge E.</creator><creator>Jabbour, Elias</creator><creator>Hochhaus, Andreas</creator><creator>Hughes, Timothy</creator><creator>Chuah, Charles</creator><creator>de Lavallade, Hugues</creator><creator>Deininger, Michael W.</creator><creator>Lipton, Jeffrey H.</creator><creator>Lomaia, Elza</creator><creator>Maness, Lori</creator><creator>Mauro, Michael</creator><creator>McCloskey, James</creator><creator>Moiraghi, Beatriz</creator><creator>Pavlovsky, Carolina</creator><creator>Rojas, Christine</creator><creator>Rousselot, Philippe</creator><creator>Sacha, Tomasz</creator><creator>Talpaz, Moshe</creator><creator>Turkina, Anna</creator><creator>Sutton, Maria Undurraga</creator><creator>Ren, Xiaowei</creator><creator>Vorog, Alexander</creator><creator>Rosti, Gianantonio</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial</title><author>Apperley, Jane F. ; Cortes, Jorge E. ; Jabbour, Elias ; Hochhaus, Andreas ; Hughes, Timothy ; Chuah, Charles ; de Lavallade, Hugues ; Deininger, Michael W. ; Lipton, Jeffrey H. ; Lomaia, Elza ; Maness, Lori ; Mauro, Michael ; McCloskey, James ; Moiraghi, Beatriz ; Pavlovsky, Carolina ; Rojas, Christine ; Rousselot, Philippe ; Sacha, Tomasz ; Talpaz, Moshe ; Turkina, Anna ; Sutton, Maria Undurraga ; Ren, Xiaowei ; Vorog, Alexander ; Rosti, Gianantonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1856-e6f0a63bf31e68e7eeb643293473173e8acbae1474366b0652a8cd74d4e57a9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Apperley, Jane F.</creatorcontrib><creatorcontrib>Cortes, Jorge E.</creatorcontrib><creatorcontrib>Jabbour, Elias</creatorcontrib><creatorcontrib>Hochhaus, Andreas</creatorcontrib><creatorcontrib>Hughes, Timothy</creatorcontrib><creatorcontrib>Chuah, Charles</creatorcontrib><creatorcontrib>de Lavallade, Hugues</creatorcontrib><creatorcontrib>Deininger, Michael W.</creatorcontrib><creatorcontrib>Lipton, Jeffrey H.</creatorcontrib><creatorcontrib>Lomaia, Elza</creatorcontrib><creatorcontrib>Maness, Lori</creatorcontrib><creatorcontrib>Mauro, Michael</creatorcontrib><creatorcontrib>McCloskey, James</creatorcontrib><creatorcontrib>Moiraghi, Beatriz</creatorcontrib><creatorcontrib>Pavlovsky, Carolina</creatorcontrib><creatorcontrib>Rojas, Christine</creatorcontrib><creatorcontrib>Rousselot, Philippe</creatorcontrib><creatorcontrib>Sacha, Tomasz</creatorcontrib><creatorcontrib>Talpaz, Moshe</creatorcontrib><creatorcontrib>Turkina, Anna</creatorcontrib><creatorcontrib>Sutton, Maria Undurraga</creatorcontrib><creatorcontrib>Ren, Xiaowei</creatorcontrib><creatorcontrib>Vorog, Alexander</creatorcontrib><creatorcontrib>Rosti, Gianantonio</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Apperley, Jane F.</au><au>Cortes, Jorge E.</au><au>Jabbour, Elias</au><au>Hochhaus, Andreas</au><au>Hughes, Timothy</au><au>Chuah, Charles</au><au>de Lavallade, Hugues</au><au>Deininger, Michael W.</au><au>Lipton, Jeffrey H.</au><au>Lomaia, Elza</au><au>Maness, Lori</au><au>Mauro, Michael</au><au>McCloskey, James</au><au>Moiraghi, Beatriz</au><au>Pavlovsky, Carolina</au><au>Rojas, Christine</au><au>Rousselot, Philippe</au><au>Sacha, Tomasz</au><au>Talpaz, Moshe</au><au>Turkina, Anna</au><au>Sutton, Maria Undurraga</au><au>Ren, Xiaowei</au><au>Vorog, Alexander</au><au>Rosti, Gianantonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>6760</spage><epage>6762</epage><pages>6760-6762</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-157956</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-4971 |
| ispartof | Blood, 2022-11, Vol.140 (Supplement 1), p.6760-6762 |
| issn | 0006-4971 1528-0020 |
| language | eng |
| recordid | cdi_crossref_primary_10_1182_blood_2022_157956 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T23%3A17%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20Response%20of%20%E2%89%A410%25%20BCR::ABL1IS%20Is%20Predictive%20of%20Positive%20Outcomes%20in%20Treatment-Resistant%20Patients%20with%20Chronic%20Phase%20Chronic%20Myeloid%20Leukemia%20(CP-CML)%20Treated%20with%20Ponatinib%20from%20the%20Phase%202%20Optic%20Trial&rft.jtitle=Blood&rft.au=Apperley,%20Jane%20F.&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=6760&rft.epage=6762&rft.pages=6760-6762&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-157956&rft_dat=%3Celsevier_cross%3ES0006497122045645%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122045645&rfr_iscdi=true |